Cronos Group Inc. CRON · NASDAQ
$3.21 +0.31% (+$0.01)
Summary
56 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 29 USD is left as net profit.
- Revenue grew by 31% a year over the last 3 years.
- It holds more cash than debt: $467.0M against $1.30M.
What to watch
- The share price is above the Bulios Fair Price.
- It earns only 1.3 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 16.9 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 33% a year over 5 years. Over the last 3 years it grew by 31% a year.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 66 USD
- Research and development 2.2 USD
- Sales and administration 26 USD
- Taxes and other -24 USD
- Net profit 29 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 29 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 3
- Hold 9
- Sell 3
Today's price within the analysts' price targets
The average target of $3.15 is 1.9% below today's price. 20% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Cannabis Flower 74%
- Cannabis Extracts 26%
- Product and Service, Other 0.3%
By region
- CANADA 62%
- ISRAEL 29%
- Other Countries 9.9%
Cannabis Flower brings in 74% of revenue. Cannabis Extracts grew fastest, by 26% a year.
Segments in detail